Progyny, Inc. (NASDAQ:PGNY) Shares Purchased by Barclays PLC

Barclays PLC grew its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 530.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 706,157 shares of the company’s stock after acquiring an additional 594,140 shares during the quarter. Barclays PLC owned about 0.83% of Progyny worth $11,835,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PGNY. Quarry LP raised its position in Progyny by 1,900.0% in the second quarter. Quarry LP now owns 880 shares of the company’s stock valued at $25,000 after purchasing an additional 836 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Progyny in the second quarter valued at about $44,000. Mendota Financial Group LLC purchased a new stake in shares of Progyny during the 3rd quarter valued at about $56,000. 1620 Investment Advisors Inc. acquired a new position in Progyny during the 2nd quarter worth approximately $97,000. Finally, nVerses Capital LLC boosted its holdings in Progyny by 925.0% in the 2nd quarter. nVerses Capital LLC now owns 4,100 shares of the company’s stock worth $117,000 after acquiring an additional 3,700 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Barclays dropped their price target on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $17.00 price target (down previously from $22.00) on shares of Progyny in a research note on Monday, December 2nd. Canaccord Genuity Group lowered their price objective on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday, November 13th. Jefferies Financial Group cut their target price on Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. Finally, Leerink Partners decreased their price target on shares of Progyny from $25.00 to $21.00 and set a “market perform” rating for the company in a research report on Thursday, September 19th. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $25.00.

Progyny Stock Up 1.9 %

PGNY stock opened at $14.89 on Tuesday. The stock has a market cap of $1.27 billion, a PE ratio of 25.67, a price-to-earnings-growth ratio of 1.64 and a beta of 1.35. The firm’s 50-day simple moving average is $15.51 and its 200 day simple moving average is $21.22. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $42.08.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). The business had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business’s quarterly revenue was up 2.0% on a year-over-year basis. During the same period last year, the firm posted $0.16 EPS. Equities analysts forecast that Progyny, Inc. will post 0.59 EPS for the current fiscal year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.